Contra-indicated in patients with a generalized hemostatic abnormality such as
hemophilia, Christmas disease, idiopathic thrombocytopenic purpura and in patients with active bleeding from a local lesion such as acute ulcer or ulcerating carcinoma; in patients who have had recent cranial, spinal, eye or ear surgery or trauma; hypersensitivity to hirudins; shock.
- TRADE NAME: Refludan (ZLB Behring)
- INDICATIONS: Anticoagulation in heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease
- CLASS: Anticoagulant (antithrombotic), Thrombin inhibitor
- HALF-LIFE: 1.3 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abciximab, Acenocoumarol, Clopidogrel, Eptifibatide, Streptokinase, Thrombolytics, Ticlopidine, Tirofiban, Vitamin K antagonists, Warfarin
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
